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Abstract
Over the past two decades, polymersomes have been widely investigated for the delivery of diagnostic and therapeutic agents in
cancer therapy. Polymersomes are stable polymeric vesicles, which are prepared using amphiphilic block polymers of different
molecular weights. The use of high molecular weight amphiphilic copolymers allows for possible manipulation of membrane
characteristics, which in turn enhances the efficiency of drug delivery. Polymersomes are more stable in comparison with
liposomes and show less toxicity in vivo. Furthermore, their ability to encapsulate both hydrophilic and hydrophobic drugs,
significant biocompatibility, robustness, high colloidal stability, and simple methods for ligands conjugation make
polymersomes a promising candidate for therapeutic drug delivery in cancer therapy. This review is focused on current devel-
opment in the application of polymersomes for cancer therapy and diagnosis.
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Introduction
Globally cancer is one of the prominent causes of death, thus
representing a major public health-related problem. Many
medical interventions, such as chemotherapy, radiation thera-
py, and surgical removal for the conventional management of
cancer, lack specificity and also damage the nearby healthy
cells of the body [1]. The use of nanotechnology has currently
become a popular technique for cancer treatment and
management. Nanotechnology-based approaches to target tu-
mor cells mainly focus on enhancing the bioavailability of
anti-cancer drugs and reducing toxicity. Polymersome-based
therapeutic drug delivery strategies have shown remarkable
potential in the therapy of cancer due to their physical and
chemical robustness, high drug loading capability, high col-
loidal stability, significant biocompatibility, and their ability to
encapsulate both hydrophilic and hydrophobic molecules [2].
Polymersomes are spherical nanostructures made up of
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amphiphilic block copolymers, in which a hydrophobic bilay-
er encloses an aqueous core [3, 4]. Surface modification of
polymersomes with target-specific ligands, which binds espe-
cially to the receptors over-expressed on tumor cells, can im-
prove the cellular uptake of anti-cancer molecules [5, 6]. In
comparison with healthy cells, polymersomes are progressive-
ly internalized by cancer cells and are less toxic, even at high
levels [7]. After systemic administration, polymersomes as-
semble passively at the tumor site via enhanced permeation
and retention (EPR) effect and release the drug at the target
site [8]. The integration of stimuli-sensitive chemistry can also
control the drug release from polymersomes [9]. Because of
these benefits, polymersomes have been widely explored in
numerous biomedical applications, for example, in drug deliv-
ery [10], gene delivery [11], and diagnostics [12].
Design and preparation of polymersomes
The scientific development of a number of controlled radical
polymerization (CRP) methods, such as reversible addition-
fragmentation chain transfer polymerization (RAFT), atom
transfer radical polymerization (ATRP), and nitroxide-
mediated polymerization (NMP), has resulted in the synthesis
of well-defined amphiphilic polymers [13]. Through CRP, it
is possible to synthesize functional polymers with specific
molecular weight, precise architectures, and low dispersity,
such as block, triblock, and graft copolymers [14]. Many stud-
ies have reported the self-assembly of amphiphilic polymers
in the form of spheres, cylinders, and polymersomes [15]. It is
mainly the packing parameter (p = v / al) that predicts the most
likely structure of the self-assembled aggregate in solution by
taking into account the volume of the hydrophobic block (v),
the contact area of the head group (a), and the length of the
hydrophobic block (l). If p < 1/3, spheres are formed; between
1/3 < p < 1/2, cylinders are formed; and when 1/2 < p < 1,
polymersomes are formed [16].
When the concentration of block copolymers exceeds the
critical aggregate concentration in a solution, block copolymer
undergoes self-assembly to form high molecular weight ag-
gregates [17]. Amphiphilic block copolymers show extremely
slow chain exchange dynamics and exhibit a low critical ag-
gregate concentration [17–19]. As a result, polymersomes are
retained in the bloodstream for a longer duration. The thick-
ness of the membrane in polymersomes can be tailored by
adjusting the molecular weight of the amphiphilic polymers,
which can affect their physicochemical properties such as me-
chanical stability and toughness [20]. Non-biodegradable
polymers such as poly (styrene), poly(dimethylsiloxane),
poly(ethyl ethylene), poly(butadiene), and biodegradable
polymers like poly(lactide) and poly(ε-caprolactone) primari-
ly constitute the hydrophobic part of the block copolymer. The
hydrophilic part is mainly formed by polymers like poly(-
acrylic acid), poly(ethylene glycol) (PEG), and poly (L-
glutamic acid) [21]. PEG is commonly used as a hydrophilic
constituent of di- and triblock copolymers to prevent the plas-
ma protein adsorption and thus maintains the stability of the
carrier in the plasma [22, 23]. Its neutral and hydrophilic na-
ture makes polymersomes imperceptible to dendritic and
phagocytic cells [24]. Figure 1 illustrates the typical structure
of polymersomes. The core section of the polymersomes con-
tains hydrophilic molecules, and the hydrophobic bilayer can
be designed to load hydrophobic molecules [25, 26].
The preparation of polymersomes generally involves the
addition of an amphiphilic polymer in the selective organic
solvent to form an organic phase. The polymer containing
organic phase is then added to the aqueous phase. Mixing
enables the formation of a fine dispersion of the polymer in
the aqueous phase and the amphiphiles self-assemble to form
polymersomes [15]. Several techniques can be exploited to
prepare polymersomes such as nanoprecipitation (solvent-ex-
change method), film rehydration, electroformation, and
emulsification methods (oil-in-water emulsion method and
double emulsion method) [27, 28]. The technique used to
self-assemble the polymersomes can influence the size of
polymersomes. Methods such as electroformation, double-
emulsion result in the formation of polymersomes in microm-
eter size range, while polymersomes in the size range of nano-
meter are prepared using the film rehydration and
nanoprecipitation method [29–32]. The polymersomes struc-
ture can be additionally modified by external factors such as
sonication, freeze/thaw cycles, and extrusion through polycar-
bonate filters [32–35]. Though it is possible to load the mol-
ecules during the formulation processes, it is more often fa-
vored to load molecules post-fabrication to circumvent harm-
ful effects on the carrier. Some of the post-fabrication tech-
niques to encapsulate drugs in polymersomes are extrusion,
electroporation, and ultrasonication [36]. Table 1 gives an
overview of the methods used for the preparation of
polymersomes.
Several methodologies have been adopted to conjugate
ligands on the surface of nanoparticles such as click
chemistry, oxime chemistry, thiol-ene chemistry, and
inverse-electron demand Diels-Alder reactions [41].
Among them, click reactions are widely employed to con-
jugate ligands onto the surface of polymersomes [42, 43].
The thickness and fluidity of the membrane are affected
by the nature of the block copolymer (tri or di-block) and
molecular weight of the building blocks [28, 44, 45].
Triblock copolymers, having the same molecular weight
as di-block copolymers, form thinner membranes and
block copolymer with high molecular weight, form a
thicker membrane [26]. The fast absorption of drug car-
riers by the mononuclear phagocyte system is one of the
important challenges in targeted drug delivery [46].
Several factors, such as the degree of PEGylation, size
and surface charge of nanoparticles, can influence the
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uptake of polymeric nanoparticles by the mononuclear
phagocyte system [47, 48]. In addition, the presence of a
tumor also significantly influences the circulation time of
polymersomes [49]. Therefore, it is important that long-
circulating nanocarriers should be designed judiciously
for the adequate accumulation of nanocarriers via passive
targeting at the tumor site. The presence of high charges
on the surface of carriers may also decrease their circula-
tion time by enhancing hepatic uptake [28]
Drug encapsulation in polymersomes
Drug encapsulation is an important factor that needs to be
considered in the preparation of drug delivery systems. For
the encapsulation of hydrophobic and hydrophilic molecules
in the polymersomes, both active and passive loading ap-
proaches have been employed. In the passive loading ap-
proach, the hydrophilic molecules are typically added to the
aqueous phase during the preparation of polymersomes.
Table 1 Different methods of





Nanoprecipitation The amphiphilic block copolymer is first dispersed in an organic solvent, and then slowly
mixed with the aqueous phase under stirring conditions. The polymer containing organic
phase diffuse into the aqueous medium and the polymermolecules self-assemble to form
polymersomes.
Film rehydration In this technique, the amphiphilic copolymer is first dispersed in an organic solvent such as
dichloromethane or dimethylsulfoxide, and the solvent is then evaporated, permitting the
formation of a thin polymeric film layer. After the thin film layer is obtained, the addition
of the aqueous phase leads to the formation of polymersomes.
Electroformation In electroformation method, the amphiphilic copolymer is dissolved in a volatile organic
solvent, generally chloroform, with a concentration of 20 mg/mL. Evaporation of the
solvent leads to the formation of a polymer film on the surface of electrodes. The
polymer film is then hydrated using an aqueous solvent with an applied alternating
current (5 V), which results in the release of the formed polymersomes. This method is
generally used to prepare giant polymersomes (> 1 μm).
Emulsification Oil-in-water (o/w) single emulsion method
In this method, the amphiphilic copolymer is first dispersed in a partly water-immiscible
organic solvent. The polymer solution is then mixed with the aqueous phase under
vigorous stirred conditions. The organic solvent is later removed by filtration or
evaporation methods.
Double-emulsion method
In the double-emulsion method, the amphiphilic copolymer is first dissolved in an organic
phase and the organic phase is then emulsified with an aqueous solvent containing a
surfactant or stabilizer to form a water in oil emulsion (w/o). The w/o emulsion is added
to a larger volume of the aqueous phase. The solvent is then slowly evaporated, resulting
in the self-assembly of the polymers into vesicular structures.
Fig. 1 2-D cross-sectional
schematic representation of the
biodegradable polymersome,
containing hydrophilic drug
loaded within its core. The
hydrophobic drug can be loaded
within the hydrophobic
membrane. The surface of
polymersomes can be further
modified with selective targeting
moieties
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Several active liposomal loading techniques (such as salt and
pH gradient) can also be employed if the water solubility of
drugs is low or to achieve high encapsulation efficiency [50,
51]. The hydrophobic molecules are generally added to the
requisite organic solvent along with the amphiphilic polymers
and incorporated into the polymersomemembrane during ves-
icle formation [27, 37].
Advantages and limitations of polymersomes in
comparison with those of liposomes
Polymersomes and liposomes have their respective advan-
tages and limitations. Liposomes have been extensively stud-
ied for the delivery of a variety of therapeutic agents and are
considered one of the best drug delivery vehicle systems. A
significant drawback of liposomes is their poor biochemical
and mechanical stability in complex fluids, such as blood,
which might result in the premature and uncontrolled release
of therapeutic payload [52]. Polymersomes are more stable in
comparison to their lipid counters, such as liposomes due to
their membrane thickness, lateral diffusivity, and entangle-
ment [53]. However, such properties, in particular, depend
on many different aspects such as the size of polymeric vesi-
cles, method of preparation, nature of amphiphiles, and stor-
age conditions [16]. The bilayer membrane in polymersomes
is typically much thicker (~ 50 nm) in comparison with that in
liposomes (3–5 nm) [16, 53, 54]. Therefore, higher amounts
of hydrophobic drugmolecules can be accommodated into the
thicker hydrophobic bilayer of polymersomes compared to
liposomes. Moreover, thicker membranes may result in a
slower release of hydrophobic drug molecules because of
the large diffusion distances [55]. However, polymersomes
have relatively low loading capacity for hydrophilic mole-
cules, limiting their applications as drug carriers, particularly
for anti-cancer therapy [56]. The robustness and stablility of
bilayer membrane of polymersomes can also be a disadvan-
tage. However, due to their chemical versatility, it is also
possible to program the release of the cargo using several
external and internal stimuli. The polymersomes show better
colloidal stability against mechanical shear and osmotic pres-
sure in the bloodstream than liposomes because of the high
molecular weight of block copolymers [57]. Polymersomes
exhibit relatively low permeability toward macromolecules,
ions, and small molecules, and this drawback also hinder their
use in biomedical applications [58]. Liposomes are considered
more biocompatible in comparison to polymersomes as the
polymersomes are prepared using synthetic building blocks.
Therefore, polymersomes degrade slowly and also show
higher toxicity compared to liposomes [59].
The pharmacokinetics and biodistribution profile of
polymersomal and liposomal formulations have been
reviewed in several papers. Alibolandi M. et al. investigated
the distribution and therapeutic efficacy of doxorubicin-
loaded polymersomes (Poly-DOX) with a liposomal formula-
tion in murine colon adenocarcinoma model [60]. Findings of
the study revealed that Poly-DOX favorably accumulated in
the tumor and was present in significantly lower concentra-
tions in the liver 48 h post-treatment than the liposomal for-
mulation. The tolerated dose in mice receiving Poly-DOXwas
remarkably lower than those receiving the liposomal formu-
lation. Poly-DOX demonstrated better therapeutic efficacy in
terms of tumor growth rate and can potentially limit off-site
effects. In another study, a comparison between the pharma-
cokinetic properties of DOX-loaded polymersomes
(PolyDoxoSomes) and a commercially available liposomal
DOX (Lipo-DOX) have been reported [61]. It was observed
that the PolyDoxoSomes exhibited shorter plasma half-life
(22 vs. 35 h) and lower area under the curve (AUC) (568 vs.
229 μg h/ml), which could be valuable for reducing the side
effects and dose-related toxicities. The therapeutic efficacy of
the polymersomal formulation was equivalent to that of the
Lipo-DOX. In a similar study, Zou et al. prepared DOX-
loaded cNGQGEQc peptide decorated redox-sensitive
polymersomes [62]. Pharmacokinetic and biodistribution
studies revealed that the prepared formulation had a longer
circulation time and significantly higher tumor accumulation
in mice when compared with treatment with Lipo-DOX. The
prepared formulation showed a 6-fold higher maximum-
tolerated dose in mice than Lipo-Dox. Youssef S. F et al.
prepared flutamide-loaded polymersomes and investigated
their in vivo pharmacokinetics compared with the liposomal
formulation after oral administration [63]. They observed that
flutamide-loaded polymersomes exhibited 3.9- and 4.7-times
higher plasma concentration than liposomes and drug suspen-
sion. GE11 peptide-modified polymersomes loaded with
DOX were prepared by Zou Y et al. for the treatment of
SKOV3 human ovarian tumors [64]. In vivo biodistribution
studies showed a more significant tumor accumulation of the
polymersomal formulation compared to Lipo-DOX. The pre-
pared formulation effectively suppressed the progression of
SKOV3 tumors (IC50 = 8.7 DOX equiv./mL) and showed
low toxicity compared to Lipo-DOX in in vitro studies.
Mechanisms of drug release
from polymersomes
Drug release from polymersomes generally occurs through
passive diffusion, which is mainly driven by concentration
gradients. In recent years several stimuli-responsive
polymersomes have also been developed to achieve controlled
release of their payload on reaching to the target site in re-
sponse to external or internal stimuli [65]. Their ability to
trigger drug release at the target site can significantly enhance
therapeutic efficiency and may diminish its adverse effects.
Stimuli-responsive polymersomes can be designed to release
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the therapeutic agent in response to either chemical (mainly
induced by pH and redox molecular chain composition) and
physical triggers (temperature, light, magnetic, electrical, and
ultrasound) at the target site [25, 66]. These intelligent nano-
structures can effectively receive, transmit, and react to stim-
uli. Figure 2 displays stimuli-responsive, intracellular drug
release by polymersomes in the target diseased cell. The stim-
uli characterized as abnormal temperature, pH, oxidative
stress, and abnormal glucose levels, typical to the unhealthy
cells, prompt the intracellular dissolution of the polymersome
backbone to release the encapsulated drug molecules. Over
the years, several types of stimuli-responsive polymersomes
[25] like pH- [67], enzyme- [68], photo- [69], glucose- [70],
voltage- [71], and magnetic field-responsive polymersomes
[72] have been developed.
Categories of polymersomes
Based on stimuli response, polymersomes can be categorized
in various classes, which are discussed below:
pH-responsive polymersomes
pH-responsive polymersomes have recently gained significant
attention due to the existence of physiological pH gradients
within the body. Acidic extracellular pH is the main feature of
the tumors and inflammatory tissues (pH ∼ 6.5 − 7.2) [73].
Several pH-responsive polymersomes have been developed
by the incorporation of pH-sensitive or ionizable bonds in
the amphiphilic polymer to trigger the polymersome degrada-
tion and drug release [65]. Some of the earliest pH-responsive
polymersomes developed, comprised of hydrolysis-
susceptible polyester such as poly(lactic acid) (PLA) or
poly(ε-caprolactone) (PCL) [74]. The hydrolysis of the ester
bonds linking the polymer blocks leads to polymersome deg-
radation and drug release. Ahmed et al. prepared ph-
responsive polymersomes based on PEG-PLA and PEG-
PCL for the delivery of anticancer drugs to the tumor tissues.
The pH-gradient method was used to load DOX into the
polymersomes and loading of paclitaxel was done after vesicle
formation. The authors found that the prepared polymersomes
accumulated in tumor tissue in mice and released the encap-
sulated payloads in the acidic tumor environment [51]. In
recent years, linkers comprising various acid-sensitive groups
like hydrazine, imine, acetal, orthoester, and vinyl ester have
also been employed to prepare polymersomes, which can in-
duce the cleavage of such systems in a pH-dependent manner
and release of the encapsulated cargo [66, 75–77].
Hydrazone linkage is one of the most commonly used pH-
sensitive bonds that have been employed in drug delivery
systems on account of its faster rate of hydrolysis in an acidic
pH environment [78]. Brinkhuis et al. formulated
polymersomes composed of a mixture of polybutadiene–
Fig. 2 Schematic illustration of the reduction-responsive drug release from polymersomes. The cleavage of the disulfide bonds by the GSH activates the
disassembly of the polymersomes leading to subsequent drug release.
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PEG amphiphilic block copolymers coupled via an acid-
sensitive hydrazone linkage. The prepared polymersomes
retained their colloidal stability at physiological pH and
disassembled under slightly acidic conditions [77]. pH-
triggered degradation of polymersomes can also be achieved
by incorporating ionizable groups into the polymer blocks.
pH-sensitive polymers with ionizable groups typically have
weakly acidic (carboxylic acids/sulfonic acids) or weak basic
groups (amine) that undergo protonation or deprotonation in
response to change in environmental pH. When the environ-
mental pH is lower than the pKa for specific group side chains
of copolymers, the basic groups are protonated, and the integ-
rity of the vesicle is affected by electrostatic repulsion [79].
Structural transformation can subsequently cause
polymersome formation/deformation, resulting in a higher
therapeutic index due to the rapid release of therapeutics at
the target site. Armes and co-workers formulated zwitterionic
poly(2-(methacryloyloxy)ethylphosphorylcholine)-b-
poly(2-(diisopropylamino) ethyl methacrylate) (PMPC-b-
PDPA) block copolymer to prepare stable vesicles [80]. The
vesicles were stable at physiological pH due to the acidic pKa
of the tertiary amine group in PDPA. Under acidic conditions,
degradation of vesicles occurred due to the protonation of the
amine groups in PDPA, which is hydrophobic at physiologi-
cal pH and hydrophilic under acidic solutions. In another
study, Massignani M. et al. formulated polymersomes com-
prising PMPC-PDPA diblock copolymers. The prepared
polymersomes exhibited both cell affinity and pH-sensitivity
and effectively delivered the cargo within the cell cytosol [81].
Cationic polymers, including poly(lysine), poly(histidine),
and poly(β-amino ester), and anionic polymers, like
poly(methacrylic acid) and poly(acrylic acid), are pH-
responsive [25, 82–85]. Cationic polymers with pH-
sensitivity can modify the drug taste and gastric release of
drugs by reacting to low pH of the stomach. Anionic polymers
sensitive to the high intestinal pH are utilized to prevent the
degradation of the drug in the stomach, drug delivery in the
colon, and to increase the bioavailability of weakly basic
drugs [78]. Cationic polymers comprising amino groups show
greater solubility at acidic pH in aqueous solutions as com-
pared to neutral pH [86]. This results in the pH dissolution of
the polymer and the release of drugs into the target cell.
Temperature-responsive polymersomes
Temperature-responsive polymersomes consist of
temperature-sensitive polymers that exhibit a phase transition
or conformational changes in response to temperature stimuli.
The phase transitions induce changes in hydrophilicity/
hydrophobicity balance and solubility of polymers that lead
to the formation/disintegration of vesicles [87]. Some thermo-
responsive polymers applied in drug delivery systems exhibit
a low critical solution temperature (LCST), which become
insoluble upon heating. Many thermo-responsive polymers
have an upper critical solution temperature (UCST), which
become soluble upon heating [88]. This property has been
exploited in cancer therapy, as the local temperature is slightly
higher in solid tumors than the temperature in adjacent normal
tissues. The local cooling of the tissues by the application of
external ice packs or by penetrated cryoprobes can also be
used to distort the polymersome vesicles to release the thera-
peutic drug [89].
Poly-N-isopropyl acrylamide (PNIPAm) is a thermo-
responsive polymer that is often used to prepare temperature-
sensitive polymersomes. PNIPAm, which has an LCST of 32
°C, can self-assemble at normal body temperature (37 °C) to
form stable polymersomes and disassemble to release the load-
ed therapeutic agent at temperatures below its LCST [66]. Qin
et al. formulated thermoresponsive polymersomes based on
diblock copolymer PEO-b-PNIPAM [90]. These polymers
could self-assemble into polymersomes in water above body
temperature, encapsulating both hydrophobic and hydrophilic
molecules. With a decrease in temperature (below 32 °C), the
PNIPAM becomes hydrophilic, causing vesicles to disassem-
ble and release the encapsulated cargo.
The tri-block copolymers of PEG-PAA-PNIPAm have
been used to prepare polymersome with dual triggers response
(temperature and reduction responsive) [91]. Increasing the
temperature over the LCST of polymer contributed to the
development of polymersomes in the aqueous environment.
Crosslinking the vesicles with cystamine produced robust
polymersomes at human body temperature. However, due to
the presence of cystamine in the structure, these polymers
were sensitive to a reductive environment. Kharlampieva
and co-workers prepared DOX-loaded temperature-sensitive
polymersomes of poly (3-methyl-N-vinylcaprolactam)-block-
poly (N-vinylpyrrolidone) (PMVC-PVPON) [92]. By reduc-
ing the length of the PVPO block, the LCST of the copolymer
PMVC-PVPON can be varied from 19.2 to 15.2 °C. The
prepared polymersomes showed a remarkably high loading
capacity of 49%. The formulation exhibited good structural
stability in serum.
Redox-responsive polymersomes
The development of redox-responsive polymersomes permits
the loading of both hydrophobic and hydrophilic therapeutic
agents, and the simultaneous release of multiple therapeutic
loads can enhance the therapeutic efficacy of the delivery
system [93]. Redox potentials differ significantly between
the tumor cells and normal tissue, the extracellular and intra-
cellular environment, and between different cell organelles
[94]. Polymersome, which reacts to change in redox potential,
often contain disulfide bonds [95]. Disulfide bonds are sus-
ceptible to reduction and get reduced to two thiols in reductive
environments. The concentration of glutathione (GSH) is
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typically low in plasma and normal tissues but much higher in
the nuclei, cytosol, and tumor tissue, which produces a high
intracellular redox gradient [65]. Disulfide bonds are incorpo-
rated into the polymeric backbone and subsequent cleavage of
these bonds triggers the degradation of the polymersomes
resulting in the release of the therapeutic payload [95]. The
intracellular reducing environment and oxidizing nature of the
extracellular environment may be utilized to activate the drug
release from polymersomes.
Ren et al. prepared DOX-loaded redox-responsive poly-
meric vesicles self-assembled from triblock copolymers with
disulfide bond linked PEG and poly(ε-benzyloxycarbonyl-l-
lysine) (PzLL) for glutathione (GSH)-mediated drug release
[96]. The cleavage of the disulfide bonds by the GSH can
activate the disassembly of the vesicles to release the cargo
within the cells. DOX-loaded vesicles demonstrated higher
nuclear accumulation after incubation with HeLa cervical can-
cer cells after exposure to GSH and were helpful in reversing
drug resistance. In a similar study, Kumar A. et al. prepared
DOX-loaded polymersomes based on redox-sensitive amphi-
philic triblock copolymer pPEGMA-PCL-ss-PCL-pPEGMA
[97]. The intracellular GSH triggered the degradation of the
polymersomes after the cleavage of the disulfide bonds in the
polymeric backbone, leading to intracellular drug release.
Furthermore, the prepared redox-responsive polymersomes
showed enhanced anti-tumor efficacy without showing any
significant cardiotoxicity.
Several recent studies have reported the preparation of
oxidation-sensitive polymersomes that can deliver the thera-
peutic agents to the target site. Oxidation by reactive oxygen
species like hydrogen peroxide (H2O2) or oxidation stress at
the tumor site leads to the destruction of polymeric assem-
blies. Li et al. prepared glucose oxidase-loaded polymersomes
made up of diblock copolymers of PEG and copolymer of
camptothecin (CPT) and piperidine-modified methacrylate
[98]. At the tumor site, the acidic environment of the tumor
triggered the generation of H2O2. High levels of H2O2 induces
self-destruction of the polymersomes to release CPT, which
suppressed the growth of tumor through the synergistic action.
Other stimuli-responsive polymersomes
Polymersomes loaded with magnetic nanoparticles have also
been investigated for the controlled delivery of therapeutic
and imaging agents when exposed to an external magnetic
field. By the application of local hyperthermia, the encapsu-
lated hydrophilic magnetic core can be released at the target
site [72, 99]. Photo-responsive polymersomes have also re-
ceived great attention because of their ability to release the
cargo at specific sites by exposure to light. Photo-sensitive
moieties can be incorporated into the amphiphilic block poly-
mers to make them sensitive to the wavelengths of light [100].
A photo-cleavable linker (o-nitrobenzyl) that forms a photo-
labile bond between the hydrophilic and hydrophobic sections
of polymers has also been reported. UV radiation exposure at
365 nm induces bond cleavage and eventually shrinks the
material, which allows the release of an encapsulated drug.
The frequency of UV light can also be used to monitor the
release of material as well [101]. A major drawback of
adopting this strategy is that UV irradiation is required for
efficient release of encapsulated cargo at 365 nm wavelength,
which can destroy healthy tissues as well.
The specific overexpression of certain enzymes in the tu-
mor microenvironment can be utilized to deliver drugs at a
particular site. In recent years several enzyme-sensitive
polymersomes have been prepared in which the polymer
blocks are linked through enzyme cleavable groups that en-
able the release of encapsulated payloads from nanocarriers at
the target cell. Lee et al. formulated polymersomes based on
mPEG and PDLLA (mPEG: methoxy poly(-ethylene glycol),
PDLLA: poly(D,L-lactide) block copolymer [102]. A Gly-
Phe-Leu-Gly-Phe (GFLGF) linker was then incorporated in
between the two blocks. The block copolymer was cleaved
at the tumor site by Cathepsin B (found in abundance in tumor
tissues) causing disassembly and the release of chemotherapy
agents from the prepared systems.
Iatridi et al. investigated pH and temperature-responsive,
star-graft quarterpolymer-based polymersomes as carriers for
the controlled co-delivery of paclitaxel (hydrophobic) and
DOX (hydrophilic) [103]. The release profile of both the che-
motherapeutic agents was controlled in a different way de-
pending upon the environmental conditions (temperature and
pH). The polymersomes displayed higher cytotoxicity in the
A549 cancer cell lines in comparison with the single-loaded
polymersomes. In another study, Chen et al. prepared ultra-
sound and pH-responsive polymersomes loaded with DOX.
Upon irradiation with ultrasound and by decreasing the pH of
the solution, the vesicles became smaller and released the
encapsulated anti-cancer drugs in a controlled manner [104].
Polymersomes in various cancer therapy
Recent advances to encapsulate and deliver various therapeu-
tic agents using polymersomes for the treatment of different
types of cancer are discussed below. The characteristics and
anti-cancer activity of the polymersomes based formulations
are summarized in Table 2.
Polymersomes for brain cancer therapy
In brain tumor treatment, drug delivery via the blood-brain
barrier (BBB) that primarily prevents the entry of large num-
bers of molecules into the brain has become an important
concern among the scientific community [33, 137].
Innovation in nanomedicine has contributed to polymersome
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development as an appropriate carrier for drug delivery in
brain cancer treatment. BBB is highly expressed with a pleth-
ora of receptors, such as low-density lipoprotein receptor
(LDLR), transferrin receptor, and insulin receptor, which can
be utilized for receptor-mediated transcytosis (RMT) of
nanomedicine through BBB [138, 139].
Surface functionalization of polymersomes with antibodies
such as lactoferrin (Lf) and transferrin (Tf) has been reported
to improve the delivery of therapeutic agents to the brain.
Pang et al. developed biodegradable polymersomes loaded
with DOX (Tf-PO-DOX) using the nanoprecipitation method
to improve the DOX delivery into brain tumor cells [108]. The
researchers eventually conjugated transferrin to the
polymersome surface. In contrast to the free DOX, the devel-
oped formulation considerably improved the intracellular de-
livery and chemotherapeutic effect of DOX in glioma-bearing
rats. The pharmacokinetics studies revealed that Tf-PO-DOX
significantly reduced the plasma clearance of DOX (from
1038 to 101 mL/h/kg) and showed 19-fold higher AUC com-
pared with free DOX. In addition, tissue accumulation of
polymersomes was higher in the liver but lower in the heart,
suggesting that the polymersome DOX may have the same
potency as Doxil® (liposomal doxorubicin). Pang and co-
workers formulated tetrandrine and DOX-loaded biodegrad-
able polymersomes conjugated with lactoferrin (Lf-PO-DOX/
Tet) [140]. The outcomes of the study revealed the enhanced
cellular uptake of LF-PO-DOX/Tet and cytotoxicity toward
C6 cells. The prepared formulation effectively inhibited the
glioma growth and enhanced the survival time of glioma-
bearing rats. In another study, Pang et al. compared the rela-
tive superiority of polymersomes conjugated with Tf and Lf
(Tf-PS and Lf-PS) in brain targeting [141]. The findings of the
in vitro cellular uptake studies in mice revealed enhanced
brain uptake of Tf-PS in comparison with Lf-PS. The phar-
macokinetic study displayed a similar plasma concentration-
time profile for both Tf-PS and Lf-PS. Tf-PS showed a 1.84-
fold higher AUC compared with Lf-PS. Furthermore, the dis-
tribution and elimination rate constants for Lf-PS were 2.11-
and 3.12- fold higher compared with that for Tf-PS.
Apolipoprotein E peptide (ApoE) has an active penetrating
function across the BBB due to its high affinity to multiple
LDLRs and can be used to target intracranial glioma [142]. In
2018, Jiang Y. et al. prepared apolipoprotein E peptide modi-
fied chimeric polymersomes (ApoE-CP) carrying saporin
(SAP) [143]. The in vitro BBB model studies indicated that
ApoE-CP exhibited 2.2-fold higher penetration compared with
Angiopep-2–modified chimeric polymersomes. Administration
of the prepared formulation via the systemic route in the glio-
blastoma bearing mouse model resulted in total inhibition of
orthotopic U-87 MG glioblastoma cells (IC50 = 14.2 nM), and
no adverse effects were observed. The histological analyses
revealed that ApoE-CP-SAP did not induce damage to major
organs. Qin et al. prepared ApoE peptide targeted chimaeric
polymersomes loaded with rigosertib (ApoE-CP-RGS) to over-
come the BBB barrier [10]. The polymersomal formulation
exhibited a 3.8-fold higher cellular uptake in the U-87MG cells
in comparison to the non-targeted formulation. The ApoE-CP
showed steady loading of RGS into its lumen and reduction-
responsive release behavior of the drug. ApoE-CP-RGS
showed significant cytotoxicity towards U-87 MG glioblasto-
ma cells with an IC50 of 2.8 μg/mL. The formulation exhibited
considerable inhibitory effects on glioblastoma cells and
prolonged survival time in nude mice bearing U-87 MG glio-
blastoma. Furthermore, little damage to major organs like the
heart, spleen, liver, lung, and kidney was observed in the mice
treated with ApoE-CP-RGS.
Angiopep-2 peptide can specifically bind to low-density
lipoprotein receptor–related protein 1 (LRP1) and have been
employed to deliver drugs through the BBB. DOX-loaded
biodegradable polymersomes conjugated with Angiopep-2
(Ang-PS-DOX) were formulated by Lu et al. to target LRP1
over-expressed both in glioma cells and BBB [105]. The en-
capsulation efficiency and drug loading of polymersomes
were found to be 95% and 7.94%. Ang-PS-DOX showed
considerably higher cytotoxicity and cellular uptake in C6
cells in contrast to PS-DOX. The in vivo brain distribution
and pharmacokinetic studies in glioma-bearing rat model con-
firmed the wider distribution and more abundant accumula-
tion of Ang-PS-DOX in glioma cells as compared to PS-
DOX. Ang-PS-DOX exhibited significantly higher mean res-
idence time (MRT) (4.30 vs. 1.49 h) and AUC (4.96 vs. 0.52
h/ml) compared with free DOX. The prepared formulation
significantly increased the survival time of the glioma-
bearing rats in comparison with treatment with free DOX
and PS-DOX. Figueiredo et al. prepared polymersomes con-
jugated with Angiopep-2 and evaluated their potential of ac-
tive targeting and delivery of DOX to brain cancer cells [106].
It was observed that DOX-loaded Ps-Angiopep-2 demonstrat-
ed an enhanced cytotoxic effect on U87 MG glioblastoma in
comparison with non-targeted polymersomes.
Chen et al. formulated des-octanoyl ghrelin and folate con-
jugated polymersomal DOX (GFP-D) to aid in transportation
through the BBB to target tumors [107]. Pharmacokinetic
studies in mice revealed that GFP-D solutions showed signif-
icantly higher AUC (724.90 vs. 15.4 mg/mL*h), longer ter-
minal half-life (47.66 vs. 1.6 h), and lower blood clearance
(2.06 vs. 97.2 mL*h−1) in comparison with free DOX.
However, no significant difference in AUC and blood clear-
ance was observed between GFP-D, des-octanoyl ghrelin–
conjugated polymersomal DOX, unmodified polymersomal
DOX, and folate–conjugated polymersomal DOX. GFP-D en-
hanced the accumulation of DOX by up to 3.7-fold in tumors
compared with the group treated with unmodified
polymersomal DOX. Furthermore, GFP-D demonstrated sig-
nificant anti-glioma efficacy and greatly improved the overall
survival of tumor-bearing mice.
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Polymersomes for breast cancer therapy
Breast cancer is one of the most common cancers in women,
affecting one in eight women worldwide [144]. Several au-
thors have investigated the potential of polymersome-based
drug delivery systems for the treatment of breast cancer.
Targeted delivery of chemotherapeutics at the tumor location
provides a possible strategy by raising the therapeutic index as
compared with non-targeted drugs. Folic acid conjugation has
commonly been exploited to improve the tumor disposition of
polymersomes in breast cancer cells and in preventing non-
specific cell damage. Alibolandi et al. developed folic acid
conjugated PEG-PLGA nano-polymersomes loaded with
DOX and quantum dot (FA-QD-DOX) for the chemotherapy
and imaging of breast cancer [109]. Folic acid conjugated
nano-polymersomes achieved active targeting of cancer cells
through folate receptor directed delivery. In vivo imaging ex-
periments on 4T1 breast adenocarcinoma-bearing, BALB/c
mice revealed that FA-QD-DOX nano-polymersomes accu-
mulated at the site of the tumor for 6 h post intravenous injec-
tion. In comparison with the non-targeted and free DOX, the
developed FA-QD-DOX nano-polymersomes demonstrated
enhanced therapeutic effectiveness. Furthermore, the animals
treated with FA-QD-DOX nano-polymersomes exhibited no
evidence of long-term detrimental physiological and histo-
pathological effects. Trastuzumab and folic acid conjugated
redox-sensitive biodegradable polymersomes comprising tri-
block copolymer were fabricated by Lale et al. using the
nanoprecipitation method [112]. The polymersomes exhibited
a significantly high DOX loading content of 32%. The conju-
gation of trastuzumab and folic acid significantly enhanced
the cellular uptake and apoptosis in MCF-7 breast cancer cell
lines (IC50 = 46.22 μg/mL). The in vivo experiments in mice
showed enhanced chemotherapeutic efficiency of the pre-
pared nanosystem in breast cancer treatment with negligible
cardiotoxicity in comparison with free DOX.
A stem cell marker, Epithelial cell adhesion molecule
(EpCAM) has emerged as a potential target in cancer treat-
ment due to its over-expression in adenocarcinoma cell lines.
Alibolandi et al. formulated (EpCAM)-targeted PEG–PLGA
nano-polymersomes encapsulated with DOX using a pH gra-
dient method [145]. The authors found that the prepared nano-
polymersomes could effectively deliver DOX to EpCAM-
positive tumor cells (MCF-7) as compared to non-targeted
nano-polymersomes.
The hyaluronic acid (HA) based polymersomes have
shown advantages in terms of solubility and the targeting abil-
ity of cancer cells. In order to deliver mertansin (MM1) toxin
to the Ehrlich-ascites tumor (EAT) bearing Swiss albino mice
model, Zhang et al. prepared HA shelled and disulfide
crosslinked polymersomes loaded with DOX [113]. The pre-
pared polymersomal formulation showed a high drug loading
content of 16.7%, low drug leakage under physiological
environments, and fast GSH-triggered drug release. Results
suggested that the prepared formulation could effectively tar-
get breast cancer cells and had considerable inhibitory effects
on the growth of the tumor in mice. In another study, DOX-
loaded HA-based polymersomes (HA-PCL-DOX) were de-
veloped by Shahriari et al. to target the HA-binding glycopro-
tein CD44 on breast cancer cells [8]. The prepared
polymersomes exhibited a loading content and encapsulation
efficiency of 3.6% and 54.9%. The prepared formulation also
showed significant bio-distribution and in vivo anti-cancer
activity in the mouse 4 T1 breast tumor model. In addition,
HA-PCL-DOX showed no signs of toxicity in major organs.
The uptake of HA-PCL-DOX was significantly lower in the
mice liver, which could be attributed to lesser immunogenicity
of the HA shell.
Tamoxifen-loaded PEG-PCL polymersomes were pre-
pared by Bessone et al. to investigate the effect of iRGD
peptide functionalization on cellular uptake and breast cancer
cell viability [111]. Functionalization of the polymersomes
with iRGD peptide significantly enhanced the uptake of the
polymersomes in both MCF7 and T47D breast cancer cells
and reduced the proliferation of cancer cells with self-
renewing capacity. To increase the bioavailability of DOX,
Kumar et al. formulated redox-responsive polymersomes with
disulfide linkage [95]. The prepared formulation exhibited
significantly higher cell uptake in breast cancer cell lines.
In vivo tests in EAT-bearing mice revealed a superior regres-
sion of tumors compared to free DOX with reduced
cardiotoxicity. In 2014, Xu et al. prepared polymersomes by
self-assembly of amphiphilic PEGylated polyphosphazene
(PEP) to encapsulate hydrophobic DOX base and hydrophilic
DOX [114]. The authors found that DOX, both in its hydro-
philic or hydrophobic forms, encapsulated into PEP
polymersomes with superior encapsulation efficacy. In vivo
studies on nude mice indicated that PEP polymersomes sig-
nificantly increased the survival rates without compromising
therapeutic efficiency.
Polymersomes for lung cancer therapy
Several authors have investigated the potential of
polymersome-based drug delivery systems for the treatment
of lung cancer. Aptamer conjugation has been utilized to en-
hance the accumulation of polymersomes at the tumor site.
A S 1 4 1 1 a p t a m e r s u r f a c e c o n j u g a t e d
polye thyleneglycolepoly( lac t ic -co-g lycol icacid)
nanopolymersome (Apt-GEM-NP) loaded with an anti-cancer
drug, gemcitabine (GEM) were fabricated by Alibolandi et al.
to target nucleolin-overexpressing A549 cancer cells [120].
The prepared formulation showed loading content and encap-
sulation efficiency of 8.61% and 95.32%. It was observed that
Apt-GEM-NP showed enhanced cellular uptake and cytotox-
icity in nucleolin-overexpressing non-small cell lung cancer
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cells (A549). The results of the study suggested that AS1411-
GEM-NPs could be a potential therapeutic approach for non-
small cell lung cancer treatment.
Zhong and co-workers prepared granzyme B–loaded
reduction-sensitive polymersomes (GrB-CPRPs) and investi-
gated their effectiveness in inhibiting the progression of
orthotopic human lung tumors in vivo [115]. GrB-d CPRPs
were found to be highly effective against A549 lung cancer
cells (IC50 = 20.7 nM). GrB-d CPRPs completely inhibited the
growth of tumors in orthotopic A549-Luc lung tumor–bearing
mice and significantly improved the survival rates. Yang et al.
reported the preparation of reduction-responsive chimeric
polymersomes (RCPs) functionalized with lung cancer-
specific CSNIDARAC (CC9) peptide for the targeted delivery
of pemetrexed disodium (PEM), an anti-cancer drug to tumor
cells [116]. Results validated a superior potency of PEM-
loaded CC9-RCPs to H460 cells compared with free PEM
and non-targeting PEM-RCPs. The prepared PEM-CC9-
RCPs showed higher accumulation in H460 human lung can-
cer cells in comparison with clinical formulation Alimta®.
PEM-CC9-RCPs effectively reduced the growth of H460 xe-
nografts and extended the survival time in mice in comparison
with clinical formulations, Alimta®. In addition, PEM-CC9-
RCPs showed comparable levels of aspartate aminotransfer-
ase, alanine aminotransferase, serum creatinine, and blood
urea nitrogen with PBS control indicating the absence of kid-
ney and liver toxicity. Another study reported the develop-
ment of polymersomes containing cyclic RGD peptide and
disulfide-crosslinked DOX (cRGD-PS-DOX) for targeted de-
livery of chemotherapeutic agents to human non-small cell
lung cancer cells (NSCLC) [117]. Findings of the study re-
vealed that cRGD-PS-DOX exhibited 15.2% of drug loading,
excellent stability, and outstanding targeting capacity toαvβ3
integrin over-expressed in A549 human lung cancer cells. The
in vivo pharmacokinetics and biodistribution of cRGD-PS-
DOX showed comparable elimination half-lives but 2-fold
greater tumor accumulation in comparison to Lipo-DOX and
PS-DOX. cRGD-PS-DOX effectively inhibited the growth of
A549 lung tumors in both orthotopic and subcutaneous
models as compared with treatment with Lipo-DOX and PS-
DOX.
Yang et al. investigated the loading and targeting efficiency
of disulfide-crosslinked chimeric polymersomes loaded with
MTX sodium in sigma receptor overexpressing H460-
NSCLC xenografts [118]. The developed formulation showed
high MTX sodium loading, good in vivo stability and high
accumulation at the tumor site. The formulation showed high
potency against H460 cells with a low IC50 of 2.4 μg mL
−1,
which was 10-fold lower than that of non-targeted control. In
addition, the prepared polymersomes significantly suppressed
the tumor growth and enhanced the rate of survival in H460
tumor xenografted mice in contrast to Trexall™. In another
study, Yang and co-workers formulated selective cell-
penetrating peptide (SCPP-PS) functionalized polymersomes
for targeted delivery of MTX to human lung cancer cells
in vivo [119]. The authors observed that MTX loaded
SCPP-PS (MTX-SCPP-PS) significantly increased drug accu-
mulation in the A549 tumor and demonstrated 2.8-fold lower
IC50 (5.8 μg/mL) compared with MTX-PS and free MTX.
Most remarkably, the prepared formulation significantly sup-
pressed the progression of tumor and enhanced survival rates
in mice having A549 lung tumor xenografts as compared to
treatment with MTX-PS and free MTX.
Another study reported the development of a novel com-
posite polyphosphazene vesicle system comprising amphi-
philic and weakly cationic polymers loaded with microRNA
200c (miR-200c) [121]. The prepared system showed a sig-
nificant anti-tumor effect in nude mice bearing tumor xeno-
grafts and PTX-resistant human lung cancer cells (A549/T).
Zou et al. prepared cyclic peptide cNGQGEQc-functionalized
polymersomes for DOX delivery to lung cancer cells [62].
The prepared formulation showed superior stability under
physiological conditions and quickly disassembled in re-
sponse to GSH with minimal drug leakage. The prepared for-
mulation showed a significantly higher maximum-tolerated
dose of over 100 mg/kg in mice. Pharmacokinetic and
biodistribution studies showed that the prepared formulation
had a longer circulation time and significantly improved tu-
mor accumulation when compared to treatment with Lipo-
DOX. The prepared DOX-loaded polymersomes displayed
high anti-tumor activity in A549 lung cancer cells over-
expressing the α3 and β1 integrin with quick intracellular
drug release, and effective tumor growth suppression was ob-
served in orthotropic A549 lung tumor-bearing mice.
Polymersomes for pancreatic cancer therapy
Matrix metalloproteinase (MMP) enzymes are a family of
endopeptidases that plays important roles in pathological
and physiological processes. The matrix metalloproteinase-7
(MMP-7) isozyme is overexpressed at the tumor site in pan-
creatic cancer [146]. Anajafi et al. prepared nuclear localizing
peptide (NLS) conjugated redox-responsive vesicles in order
to deliver DOX and curcumin to pancreatic tumors [123]. In
the pancreatic cancer microenvironment, MMP-7 isozyme hy-
drolyzed the peptide and exposed the NLS on the
polymersome surface, which facilitated the release of encap-
sulated cytotoxic drugs in the pancreatic tumors. The obtained
results demonstrated that the developed polymersomes were
more toxic towards the pancreatic cancer cells compared to
the normal cells. In another study, Anajafi et al. prepared
polymeric redox-responsive polymersomes loaded with anti-
cancer drugs, DOX, and GEM by using pH gradient method
[124]. To provide nuclear-localizing property, the redox-
responsive polymersomes were conjugated with acridine or-
ange (AO). The authors found that the redox-sensitive
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polymersomes released most of its embedded contents and
significantly decreased the viability and volume of the pancre-
atic cancer cell spheroids.
Iatrou et al. developed temperature and pH-responsive
polymersomes made up of amphiphilic polymers of type
ABA and ABC where A, B, and C represented poly(L-lysine
hydrochloride) [PLL], poly(γ-benzyl-(d7) L-glutamate)
[PBLG(-d7)] and poly(ethylene oxide) [PEO], respectively
[126]. The polymersomes were also loaded with a hydropho-
bic drug, PTX or hydrophilic drug, DOX. It was observed that
vesicles made up of amphiphilic polymers of the ABC archi-
tecture were smaller. In vivo toxicity studies in mice con-
firmed the non-toxic nature of the prepared polymersome for-
mulation. The in vitro drug release data revealed the faster
release of DOX and PTX from the polymersomes at lower
and higher pH, respectively. In vitro studies in BXPC3 human
pancreatic cancer cell lines revealed that DOX-loaded
polymersome made up of amphiphilic polymers of ABA type
showed comparable activity to non-PEGylated liposomal
DoxMyocet, whereas the ABC type displayed lower activity.
Karandish et al. prepared stimuli-responsive polymersomes
for anti-cancer drug delivery to the nuclei of BxPC3 cells in a
nucleus-mimicking environment [122]. The authors synthe-
sized an alkyne derivative of dexamethasone, which was con-
jugated with N3–PEG–polylactic acid polymer via click
chemistry. The combination of the developed conjugate with
a stimuli-sensitive polymer resulted in the development of
stable polymersomes. Reportedly, the prepared redox-
sensitive polymersomes releasedmost of its encapsulated con-
tents in about 80 min under a high concentration of reducing
agents. Polymersomes were also loaded with the cancer inhib-
itor, BBI608. Results revealed that BBI608 loaded
polymersomes notably decreased the viability of BxPC3 pan-
creatic cancer cells. Kulkarni et al. formulated erlotinib and
GEM-loaded hypoxia-responsive polymersomes [125].
Analysis of hypoxia-responsive release of anti-cancer drugs
from polymersomes on three-dimensional (3D) spheroid cul-
tures of BxPC-3 cells revealed that the prepared
polymersomes could significantly reduce the viability of hyp-
oxic spheroidal cultures of BxPC-3 pancreatic cancer cells.
Polymersomes for prostate cancer therapy
The surface of prostate cancer cells is overexpressed with
prostate-specific membrane antigen (PSMA) receptors. In re-
cent years, the PSMA receptors have been extensively ex-
plored as a targeting receptor for the targeted delivery of drugs
to prostate cancer cells. Karandish et al. prepared folic acid
conjugated reduction-triggered polymersomes containing
anti-cancer drugs, mocetinostat, and docetaxel (DTX) for pro-
ficient PSMA receptor-mediated targeting followed by inter-
nalization in pancreatic cancer cell spheroids [127]. These
results indicated that the conjugation of folic acid enhanced
the tumor-targeting efficiency and subsequent internalization
of the polymersomes into cultured cells. Notably, the
polymersomes encapsulating both DTX and mocetinostat sig-
nificantly reduced the cell viability of 3D spheroidal cultures
of LNCaP prostate cancer cells as compared with control and
free drugs. In another study, Li et al. developed pH-sensitive
chimeric polymersome formulation decorated with 2-[3-[5-
amino-1-carboxypentyl]-ureido]-pentanedioic acid (Acupa)
for efficient delivery of granzyme B, a therapeutic protein to
prostate cancer cells [128]. The authors found that the pre-
pared system resulted in efficient apoptosis of LNCaP cells
(IC50 = 1.6 nM). The flow cytometry and CLSM studies dem-
onstrated an apparent decrease of mitochondrial membrane
potential in LNCaP human prostate adenocarcinoma cells on
treatment with the prepared polymersomal formulation. The
prepared formulation exhibited a prolonged circulation time
and elimination half-life of 3.3 h.
Demirgoz et al. designed polymersomes functionalized
with PR_b peptide for the treatment of prostate cancer [129].
PR_b peptide effectively targets a5b1 receptors and mimics
the binding site in fibronectin. Results suggested the effective
internalization of developed polymersomes in prostate cancer
cells. Later on, the PR_b-functionalized polymersomes were
encapsulated with a therapeutic protein, tumor necrosis
factor-α (TNFα). Reportedly, the delivery of TNFα via
PR_b-decorated polymersomes significantly enhanced the cy-
totoxic potential of TNFα as compared with non-
functionalized polymersomes in vitro.
Polymersomes for liver cancer therapy
Liver cancer is the most lethal malignancies across the world
and has a less than 20% 5-year survival rate [147]. The che-
motherapeutic agents administered via a systemic route are
usually unsuccessful for liver cancer because of low tumor
uptake and rapid clearance. Targeted delivery of chemothera-
peutics to cancer cells in the liver provides a possible strategy
by raising the therapeutic index as compared to non-targeted
drugs. In 2017, Fang and co-workers formulated DOX-loaded
polymersomes functionalized with GE11 peptide in order to
effectively target the epidermal growth factor receptor
(EGFR)-overexpressing SMMC-7721 xenografts in mice
[130]. MTT assays, confocal microscopy, and flow cytometry
studies confirmed that GE11-PS-DOX could efficiently deliv-
er DOX into SMMC7721 cells as compared with non-
targeting PS-DOX and Lipo-DOX. In vivo experiments dem-
onstrated that GE11-PS-DOX showed a prolonged circulation
time and high accumulation in tumor cells. Moreover, the
prepared formulation demonstrated much better treatment
and improved the survival rate of mice bearing SMMC7721
orthotopic liver tumor as compared to treatment with PS-DOX
and Lipo-DOX. Wei et al. prepared transferrin anchored
polycarbonate-based polymersomal DOX for effective liver
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cancer therapy [131]. Most remarkably, the prepared formu-
lation demonstrated high accumulation in the transferrin
receptor-expressing human liver tumor SMMC-7721 model
in contrast to treatment with non-targeted PS-DOX and
Lipo-DOX. The prepared formulation significantly improved
the survival rates in mice and showed low systemic toxicity.
Reduction-responsive hepatoma-targeted chimeric biode-
gradable polymersomes were fabricated by Wang et al. for
intracellular protein delivery [132]. Later on, the
polymersomes were loaded with various proteins like cyto-
chrome C (CC), bovine serum albumin (BSA), and ovalbumin
(OVA). Confocal microscopy confirmed that the FITC-CC-
laden galactose-decorated reduction-sensitive chimeric
polymersomes effectively delivered the FITC-CC into
HepG2 liver cancer cells, as compared with cells treated with
free CC and FITC-CC–loaded non-targeting polymersomes.
The results indicated that CC-loaded galactose-decorated chi-
meric polymersomes showed efficient targeting capacity and
anti-tumor activity in liver cancer cells (IC50 = 2.7 nM). Also,
GrB-loaded galactose-decorated chimeric polymersomes re-
sulted in significant apoptosis of liver cancer cells.
Polymersomes for colorectal cancer therapy
Alibolandi and co-workers prepared PEG-PLGA
polymersomes functionalized with tetraiodothyroacetic acid
(tetrac) for efficient camptothecin delivery to the colon ade-
nocarcinoma [133]. Tetrac attaches specifically to the integrin
αvβ3 receptor with high affinity. Camptothecin was loaded in
the polymersomes with a loading content and encapsulation
efficiency of 4.2% and 84%. In vitro drug release studies
indicated that tetrac-conjugated PEG-PLGA polymersomes
released camptothecin in a sustained release pattern. The
polymersomal formulation demonstrated significant cytotox-
icity against integrin over-expressed C26 and HT29 colorectal
cancer cells. Moreover, in vivo studies in mice bearing C26
tumor confirmed the enhanced tumor inhibition activity of
developed polymersomes as compared to the non-targeted
formulation and free camptothecin. In another study, Goñi-
de-Cerio et al. fabricated poly(trimethylene carbonate)–
block–poly(L-glutamic acid) based polymersomes for
targeting EGFR [134]. The plitidepsin-loaded polymersome
was later evaluated for its specificity and efficacy in LS174T
and HT29 colorectal cancer cell lines. Cytotoxicity assay and
cellular uptake studies in colorectal cancer cell lines con-
firmed that prepared formulation was more sensitive to cell
lines in contrast to non-targeted drug-loaded polymersome
formulation.
Polymersomes for bone marrow cancer therapy
Multiple myeloma is a malignant cancer of the plasma cells of
the bone marrow. Polymersomes offers the opportunity to
selectively deliver therapeutic agents to the bone marrow for
the effective treatment of multiple myeloma. Zhong and co-
workers prepared CD44-targeted reduction-sensitive chimeric
polymersomes loaded with granzyme B for targeted therapy
ofmultiplemyeloma [135]. The polymersomes showed a drug
loading content of 1 wt%. The prepared formulation showed
high targeting efficiency and was found to be highly effective
against LP1 cells with a low IC50 of 8.1 nM. The in vivo
biodistribution studies confirmed the enhanced accumulation
of the formulation in both subcutaneous and orthotopic LP1
multiple myeloma tumor models. Furthermore, the formula-
tion showed reduction-responsive protein release and potent
inhibition of subcutaneous and orthotopic LP1 multiple mye-
loma tumor models in comparison with non-targeted counter-
parts. In a similar study, Gu et al. prepared CD44-specific A6
short peptide-functionalized polymersomes loaded with
epirubicin for the treatment of multiple myeloma [136]. The
polymersomes showed a drug loading content of ≈ 11 wt%.
The formulation displayed enhanced anti-cancer activity
against LP-1 cells with an IC50 of 3.9 μg mL
−1. The in vivo
pharmacokinetic studies revealed that the polymersomal for-
mulation had a prolonged circulation time with an elimination
half-life of 5.1 h.Moreover, the formulation showed enhanced
targetability and anti-cancer activity against orthotopic human
multiple myeloma xenografts in vivo compared with non-
targeted polymersomes.
Polymersomes for cancer diagnosis
Polymersomes have also been investigated as a theranostic
platform that is engineered to deliver imaging and therapeutic
agents simultaneously. Several imaging agents such as mag-
netic particles [99, 148], quantum dots (QDs) [109, 149, 150],
radionuclides [110], and fluorescent dyes [151] have success-
fully been integrated with polymersomes. Chiang et al. for-
mulated SPION-loaded pH-responsive polymersomes for
chemotherapy and magnetic resonance imaging (MRI)
[148]. The polymersomes were then loaded with DOX, and
folic acid was conjugated onto the surfaces of the
polymersomes by layer-by-layer adsorption technique. The
formulation was effectively internalized into the HeLa cells
and released its payload under the combined influence of pH
and high-frequency magnetic fields. The formulation exhibit-
ed significant cytotoxicity and showed good MRI sensitivity.
Recently, Zavvar et al. investigated the potential of PEG-PCL
polymersomes loaded with gadolinium-based QDs and DOX
for MR/fluorescence imaging and anti-tumor activity [150].
The outer surfaces of the polymersomes were then conjugated
with AS1411 DNA aptamer for targeted delivery. MR and
fluorescence imaging confirmed the accumulation of
theranostic platform at the site of the tumor. The prepared
formulation significantly inhibited tumor growth in 4T1
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tumor-bearing mice compared with the non-targeted formula-
tion. In another study, Cao et al. investigated the potential of
iodine-rich polymersomes for single-photon emission com-
puted tomography/computed tomography (SPECT/CT) imag-
ing and radioisotope therapy of 4T1 murine breast cancer in
mice. [110]. 125I-radiolabeled polymersomes showed a
prolonged circulation time and distributed mainly in organs
of the reticuloendothelial system and in tumor cells. These
iodine-rich polymersomes enabled SPECT/CT imaging and
effectively inhibited tumor growth cells in mice with signifi-
cant survival benefits.
Conclusion and future perspectives
The use of polymersomes in drug delivery has attained signif-
icant importance in recent years due to their ability to load a
wide range of drugs. The surface modification of
polymersomes with ligands and peptides, which can attach
to the specific receptors located on the cancer cells can im-
prove the targeting efficacy and cellular uptake of the thera-
peutic agents towards cancer cells. In this regard, numerous
studies have been conducted in recent years for improving the
cellular uptake and intracellular delivery of polymersomes
against cancer cell membrane markers. Identification of spe-
cific targets and related ligands is important to reduce off-
toxicity. The design and development of novel copolymers
will undoubtedly pave the way for the fabrication of
polymersomes with ideal features for incorporating a variety
of therapeutic and imaging agents. Until now, a very limited
number of polymersome-based systems have actually entered
into clinical trials. Most of the techniques used for the prepa-
ration of polymersomes have low feasibility and reproducibil-
ity for upscaling, which limits their translation into clinical
application.Most stimuli-responsive studies have been carried
out under relatively static conditions in vitro and do not guar-
antee their efficacy in the human body. The in vivo pharma-
cokinetics and biodistribution parameters are vital aspects for
evaluating the biosafety of nanocarriers. To date, there have
been limited investigations on the pharmacokinetics and
biodistribution of polymersomes. Furthermore, the safety of
polymersomes should be a primary consideration for practical
applications. Long-term toxicity and immunogenicity of
polymersomes must be evaluated to enhance this strategy fur-
ther. The effect of biodegradation on polymersome stability,
drug release, and plasma half-life has not been extensively
explored.More studies comparing the drug loading efficiency,
therapeutic efficacy, pharmacokinetics, and biodistribution of
polymersomes against strong liposome controls are needed,
whose clinical safety profile is well recognized. The develop-
ment of highly stable polymersomes with multi stimuli-
linkers, which could efficiently deliver the therapeutic load
into tumor cells, might be a promising novel strategy.
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